4.2 Article

Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience

期刊

STEM CELL RESEARCH
卷 20, 期 -, 页码 105-114

出版社

ELSEVIER
DOI: 10.1016/j.scr.2017.03.002

关键词

-

资金

  1. multinational public-private Innovative Medicines Initiative - European Commission and in kind contributions from Pfizer Ltd.
  2. H. Lundbeck A/S
  3. Janssen Pharmaceutica NV
  4. Novo Nordisk A/S
  5. AstraZeneca A/B
  6. UCB Pharma SA
  7. Bayer
  8. Lilly
  9. Fraunhofer Society (Munich, Germany)
  10. IV funding from the Medical Research Council
  11. Biotechnology and Biological Sciences Research Council (United Kingdom)
  12. Biotechnology and Biological Sciences Research Council [BB/E012841/1, BBS/B/14779] Funding Source: researchfish
  13. Fight for Sight [1456/57] Funding Source: researchfish
  14. Medical Research Council [G0301182] Funding Source: researchfish
  15. The Francis Crick Institute [10319] Funding Source: researchfish
  16. BBSRC [BB/E012841/1] Funding Source: UKRI
  17. MRC [G0301182] Funding Source: UKRI

向作者/读者索取更多资源

A fast track Hot Start process was implemented to launch the European Bank for Induced Pluripotent Stem Cells (EBiSC) to provide early release of a range of established control and disease linked human induced pluripotent stem cell (hiPSC) lines. Established practice amongst consortium members was surveyed to arrive at harmonised and publically accessible Standard Operations Procedures (SOPs) for tissue procurement, bio-sample tracking, iPSC expansion, cryopreservation, qualification and distribution to the research community. These were implemented to create a quality managed foundational collection of lines and associated data made available for distribution. Here we report on the successful outcome of this experience and work flow for banking and facilitating access to an otherwise disparate European resource, with lessons to benefit the international research community. eTOC: The report focuses on the EBiSC experience of rapidly establishing an operational capacity to procure, bank and distribute a foundational collection of established hiPSC lines. It validates the feasibility and defines the challenges of harnessing and integrating the capability and productivity of centres across Europe using commonly available resources currently in the field. (C) 2017 The Authors. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据